Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUIET Brugada Syndrome Study
ACTRN12620000934943Phase 4Not yet recruiting
- Sponsor
- Sydney Local Health District
- Start
- Oct 2020
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hydroquinidine in Brugada syndrome, sponsored by Sydney Local Health District. Primary endpoints: Epicardial activation time by ECGi, Epicardial recovery time by ECGi and 1 more. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
hydroquinidine
03
Conditions
Brugada syndrome
Beyond the preview
Go deeper on ACTRN12620000934943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000934943.